Tempus, an artificial intelligence and precision medicine company, completed the acquisition of Highline Sciences, a ​​specialized, full-service clinical contract research organization. Financial terms were not disclosed. “We are committed to improving the current clinical trial model and are always seeking new ways to advance how studies are designed and executed so that we can bring clinical trials to the patients that need them most. Highline’s approach to putting patients first aligns with our own, and we look forward to seeing what we can achieve together,” Eric Lefkofsky, Tempus Founder and CEO.